Machine Vision Based MDS-UPDRS III Machine Rating

Machine Vision Based Machine Rating of MDS-UPDRS III

The Movement Disorders Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS III) is the primary assessment method for motor symptoms in Parkinson's disease patients. Currently, movement disorder specialists conduct semi-quantitative scoring, which entails limitations such as subjectivity, weak sensitivity, and a limited number of professional physicians. This study, based on machine vision, establishes gold standard labels according to expert scoring. By using machine learning, we develop a machine rating model and compare the model's performance with gold standard rating and general clinical rating to investigate the accuracy of machine vision-based MDS-UPDRS III machine rating.

Study Overview

• Status: Recruiting
• Conditions: Parkinsonian Disorders; Machine Learning
• Intervention / Treatment: Other: video recording

• Study Type: Observational
• Enrollment (Estimated): 871

Contacts and Locations

• Study Contact: Name: Lun Liu, MD,PhD; Phone Number: 021-86-64370045; Email: jly0520@hotmail.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100050
      • Not yet recruiting
      • Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University
      • Contact: Tao Feng, MD; Phone Number: 86-010-59976611; Email: happyfym@gmail.com
    • Beijing, Beijing, China, 100730
      • Not yet recruiting
      • Beijing Hospital, Neurology Department
      • Contact: Wen Su, MD; Phone Number: 86-010-85132266; Email: suwendy@126.com
  • Fujian
    • Fuzhou, Fujian, China, 350001
      • Not yet recruiting
      • Department of Neurology, Fujian Medical University Union Hospital
      • Contact: Qinyong Ye, MD; Phone Number: 86-0591-83357896; Email: unionqyye@163.com
  • Guangdong
    • Guangzhou, Guangdong, China, 510080
      • Not yet recruiting
      • Department of Neurology, Guangdong Neuroscience Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
      • Contact: Lijuan Wang, MD; Phone Number: 86-020-83827812; Email: wljgd68@163.com
  • Hubei
    • Wuhan, Hubei, China, 430022
      • Not yet recruiting
      • Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Contact: Tao Wang, MD; Phone Number: 86-027-85726114; Email: wangtaowh@hust.edu.cn
  • Jiangsu
    • Suzhou, Jiangsu, China, 215004
      • Not yet recruiting
      • Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University
      • Contact: Chunfeng Liu, MD; Phone Number: 86-0512-68282030; Email: liuchunfeng@suda.edu.cn
  • Shanghai
    • Shanghai, Shanghai, China, 200025
      • Recruiting
      • Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      • Contact: Jun Liu, MD,PhD; Phone Number: 86-021-64370045; Email: jly0520@hotmail.com
  • Sichuan
    • Chengdu, Sichuan, China, 610044
      • Not yet recruiting
      • Department of Neurology, West China Hospital, Sichuan University
      • Contact: Huifang Shang, MD; Phone Number: 86-028-85422114; Email: hfshang2002@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

In this study, participants are mainly recruited from the Department of Neurology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, as well as from movement disorder clinics at 7 other centers. Participants are enrolled through outpatient assessment and screening. Two specialists in movement disorders independently diagnosed participants as having "Parkinsonism". In cases where there is a diagnostic disagreement, the Movement Disorder Specialist Group at the Department of Neurology, Ruijin Hospital collectively discusses and makes the decision.

Description

Inclusion Criteria:

• Meeting the diagnostic criteria for Parkinsonism established by the International Movement Disorder Society: having bradykinesia, and meeting at least one of the two criteria for resting tremor or muscle rigidity
• 20 to 80 years old
• Good compliance, voluntarily joining the study, and able to sign an informed consent form or have it signed by a legal representative

Exclusion Criteria:

• Significant cognitive impairment (MMSE ≤ 23)
• Unable to sign written informed consent or unable to complete the trial due to other reasons
• Other situations in which the researcher deems the participant unsuitable for this study
• Participation in other clinical trials

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ACC0 of machine rating vs gold standard rating	The accuracy rate when machine rating equals gold standard rating.	1 day
ACC1 of machine rating vs gold standard rating	The accuracy rate when machine rating equals the range of gold standard rating plus or minus one.	1 day
Weighted kappa of machine rating vs gold standard rating	The weighted kappa when machine rating equals gold standard rating.	1 day
Lin's CCC of machine rating vs gold standard rating	The Lin's Concordance Correlation Coefficient when machine rating equals gold standard rating.	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Accuracy rate of machine rating vs general clinical rating	Comparing the absolute residuals between machine rating and the gold standard rating with the absolute residuals between general clinical raitng and the gold standard rating.	1 day
Accuracy rate of machine facilitated rating vs general clinical rating	Comparing the absolute residuals between machine facilitated rating and the gold standard rating with the absolute residuals between general clinical raitng and the gold standard rating.	1 day

Collaborators and Investigators

• Sponsor: Ruijin Hospital
• Collaborators: Beijing Tiantan Hospital; West China Hospital; Beijing Hospital; Guangdong Provincial People's Hospital; Wuhan Union Hospital, China; Fujian Medical University Union Hospital; Second Affiliated Hospital of Soochow University

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2023
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): April 1, 2024

Study Registration Dates

• First Submitted: June 7, 2023
• First Submitted That Met QC Criteria: June 7, 2023
• First Posted (Estimated): June 16, 2023

Study Record Updates

• Last Update Posted (Estimated): June 16, 2023
• Last Update Submitted That Met QC Criteria: June 7, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Basal Ganglia Diseases; Movement Disorders; Parkinsonian Disorders
• Other Study ID Numbers: u3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No